Infusystem Holdings Inc

1. 1

   Election of Directors

   ManagementBoard: FOR

   Elect seven individuals (Kenneth D. Eichenbaum, Paul A. Gendron, Ronald Hundzinski, Beverly A. Huss, Carrie A. Lachance, Scott A. Shuda, and Dr. John J. Sviokla) to the Board to serve until the 2027 annual meeting.

2. 2

   Advisory Vote Regarding Executive Compensation (Say-on-Pay

   ManagementBoard: FOR

   Non-binding, advisory vote to approve the compensation paid to the named executive officers as disclosed in the proxy statement.

   More detail

   This advisory (non-binding) proposal asks shareholders to endorse the Company’s executive pay program as disclosed in the proxy. Management seeks ratification to validate the Compensation Committee’s approach—emphasizing variable, performance‑based pay (annual cash incentives and long‑term equity with PSUs tied to relative TSR and target‑price PSUs), clawbacks, anti‑hedging/pledging policies, and double‑trigger severance—asserting these features align executives with shareholder interests and attract/retain talent. The Board recommends FOR, citing alignment of compensation with improved financial results (record revenue, higher Adjusted EBITDA and margins in 2025) and governance safeguards such as independent oversight and an independent compensation consultant. The vote is advisory and non‑binding, but the Board and Compensation Committee state they will consider the outcome when setting future compensation. The Company discloses the specifics of target metrics, the mix of compensation (majority at‑risk), and recent CEO promotion awards (including market‑price PSUs), which investors may view positively for retention but should evaluate for dilution and pay quantum. Key risks include concentrated equity grants to executives (including a CEO promotion package) and the potential for incentive design to focus on short‑term EBITDA/revenue thresholds; however, management emphasizes multi‑year PSUs and clawback provisions as mitigants. For a sophisticated evaluator, the proposal signals a request for shareholder endorsement of both pay levels and the current incentive structure and should be weighed against realized pay, peer benchmarking, and the company’s improving operational performance.

3. 3

   Approval of an Amendment to the 2021 Equity Incentive Plan (Increase Share Reserve

   ManagementBoard: FOR

   Approve the Third Amendment to the 2021 Equity Incentive Plan to increase the total share reserve by 1,000,000 shares (from 6,000,000 to 7,000,000 shares, plus shares from the 2014 Plan as applicable).

   More detail

   This management proposal requests shareholder approval to increase the authorized share reserve under the 2021 Equity Incentive Plan by 1,000,000 shares (to 7,000,000 shares plus certain recycled 2014 Plan shares). Management argues the increase is necessary to maintain an adequate pool for future equity-based grants to attract, retain and motivate employees, directors and consultants given existing outstanding awards, historical burn rate, and planned grants tied to retention and performance. The Board describes its deliberative process—considering outstanding awards (approximately 3.38M under the 2021 Plan as of March 20, 2026), available shares, dilution impact (an estimated 5.0% incremental fully diluted overhang from the requested 1,000,000 shares) and benchmarking against peers—and concluded an increase is appropriate to support long‑term incentive programs. The proposal includes the full text of the Third Amendment (Appendix A‑1) and contemplates filing an S‑8 for the new shares if approved. Key governance considerations for a sophisticated reviewer include the size of the requested reserve relative to current outstanding awards and dilution, the company’s historical share usage and grant practices (including large CEO promotion awards in 2025), and board/committee discretion over future grant timing and recipients. While management frames the increase as prudent for retention and performance alignment, investors should assess the necessity of the full 1,000,000 share increase relative to current burn, expected hiring/promotions, and potential dilution to existing shareholders; they should also evaluate anti‑dilution mechanics, share recycling rules, and the Compensation Committee’s grant practices and disclosure. The Board recommends a FOR vote, citing the need to ensure sufficient share capacity to execute the company’s compensation strategy.

4. 4

   Ratification of Independent Registered Public Accounting Firm (Grant Thornton LLP

   ManagementBoard: FOR

   Ratify the Audit Committee’s selection of Grant Thornton LLP as the Company’s independent registered public accounting firm for fiscal year ending December 31, 2026.

Upcoming shareholder meetings at Infusystem Holdings Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.

When is the Infusystem Holdings Inc 2026 annual meeting?

Infusystem Holdings Inc (INFU) holds its 2026 annual shareholder meeting on Monday, May 11, 2026.

What is the record date for the Infusystem Holdings Inc 2026 meeting?

The record date for the Infusystem Holdings Inc 2026 meeting is Friday, March 20, 2026. Shareholders of record on or before that date are eligible to vote.

Who are the director nominees for Infusystem Holdings Inc's 2026 meeting?

The board is presenting 7 director nominees at the Infusystem Holdings Inc 2026 meeting, listed with their independence status and background.

What proposals will shareholders vote on at the Infusystem Holdings Inc 2026 meeting?

Shareholders will vote on 4 proposals at the Infusystem Holdings Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.